Author: admin

Nick Berg’s Powerful Debut Novel, “Shadows of Tehran,” Officially Released Today.

Acclaimed debut novel highlights powerful themes of resilience and courage in the chaos of Iran’s 1979 revolution, praised by Kirkus and Readers’ Favorite.

Nick Berg’s Powerful Debut Novel, “Shadows of Tehran,” Officially Released Today, Acclaimed for its Gripping Portrayal of Resilience and Courage

Fortis Publishing is proud to announce the official release of the highly anticipated debut novel Shadows of Tehran: Forged in Conflict by author Nick Berg. Available now through major retailers and independent bookstores nationwide, the novel has already garnered widespread critical acclaim for its powerful narrative, authenticity, and profound exploration of resilience and human courage in times of extreme adversity.

Inspired by true events, Shadows of Tehran intimately portrays the turbulent period of Iran’s 1979 revolution through the eyes of Ricardo, a young Iranian-American struggling to find his identity amidst a backdrop of escalating violence, political upheaval, and personal tragedy. As the Shah’s regime crumbles and revolutionary forces reshape his homeland, Ricardo endures familial betrayal, abuse, and persecution, driving him to escape the oppressive environment that threatens his life. His journey ultimately leads him from the embattled streets of Tehran to the ranks of the United States Special Forces, where he dedicates himself to the relentless pursuit of freedom, justice, and redemption.

Critics have praised Berg’s debut for its emotional intensity, thrilling narrative, and undeniable authenticity. Kirkus Reviews commended the novel as “a very impressive debut,” adding, “Berg has earned entrance to this genre club—readers will hope for further adventures.” K.C. Finn of Readers’ Favorite applauded its powerful blend of action and emotional depth, describing it as “a story that kept me hooked from start to finish, balancing vivid high-stakes action with deep, emotional storytelling that hits you hard.”

Bestselling author Damien Lewis enthusiastically endorsed the book’s authentic depiction of special forces operations, stating: “Gripping and heartfelt, this is thriller writing from one who has walked the walk and talks the talk. Nail-biting stuff, in the spirit of all highly experienced elite forces operators, this drips authenticity and tradecraft.”

Lauren Hayataka from Independent Book Review highlighted the novel’s thoughtful exploration of resilience and strength, describing it as “a blistering account of survival, identity, and resistance against the tide of history.” She further emphasized its narrative strength, observing, “Berg captures the essence of personal strength and courage that emerges in the face of seemingly insurmountable adversity.”

Early readers have echoed critics’ enthusiasm, emphasizing the novel’s profound impact. One Goodreads reviewer noted, “From the very first page, it pulled me in completely—I looked up, and suddenly, I was finished, desperate to know what happens next.”

Shadows of Tehran stands out not only as a gripping tale of survival and resilience but also as a timely exploration of the complexities of identity, duty, and human spirit amid geopolitical upheaval. Author Nick Berg, drawing deeply from his personal experiences and insights into military operations, vividly brings to life a narrative that resonates with authenticity and emotional resonance.

For more information about Shadows of Tehran or to learn more about author Nick Berg, please visit www.pnberg.com.

Media Contact:

Kate Schnak

Email: katie.schnack@smithpublicity.com

Website: www.pnberg.com

Instagram: @nick.berg3

Media Contact
Company Name: Smith Publicity
Contact Person: Kate Schnak
Email: Send Email
City: Charlotte
State: NC
Country: United States
Website: https://pnberg.com

Jordan Turnbow Emerges as a Trusted Voice in Section 8 Real Estate Investing

In an era where most real estate advice is either oversimplified or buried in jargon, one entrepreneur is bringing clarity to one of the most misunderstood strategies in the industry. Jordan Turnbow, owner of Automated REI Group, has become a leading voice in Section 8 real estate investing—a niche often ignored by traditional investors but quickly gaining momentum for its stability, consistency, and long-term potential.

With over six years of experience in property acquisitions, wholesaling, and rental strategy, Turnbow built his career by doing the one thing most gurus avoid—actually managing the process from start to finish. His focus? Helping investors of all levels break into the Section 8 space with the right properties, proper education, and full support.

“Most people hear ‘Section 8’ and immediately think it’s risky or complicated,” says Turnbow. “But in reality, if it’s done right, it’s one of the most stable investment strategies out there.”

Turnbow and his team help investors across the U.S. identify undervalued properties in high-demand areas, walk them through the Section 8 landlord approval process, and ensure their rentals are properly set up to meet HUD standards. He emphasizes strategy, due diligence, and long-term planning—something often missing in today’s quick-hit real estate world.

His credibility comes not just from theory but from execution. Clients praise his transparency, responsiveness, and ability to break complex processes into simple, actionable steps.

“It’s not about selling hype—it’s about showing people how to build something that actually lasts,” Turnbow explains. “Section 8 isn’t for everyone, but if you want consistent rent and a portfolio that can weather any market, it’s worth looking at.”

With housing demand at an all-time high and affordable rentals in short supply, Jordan Turnbow’s insights are proving to be exactly what the industry—and investors—need.

To learn more about Jordan Turnbow’s work or explore investing through Section 8, visit www.automatedreigroup.com

Media Contact
Company Name: Automated REI Group
Contact Person: Jordan Turnbow
Email: Send Email
Phone: (346) 510-4607
City: Houston
State: Texas
Country: United States
Website: www.automatedreigroup.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jordan Turnbow Emerges as a Trusted Voice in Section 8 Real Estate Investing

Automated REI Group Launches Systemized Approach to Simplify Section 8 Real Estate Investing

The path to real estate ownership is often paved with roadblocks—confusing paperwork, unreliable contractors, and overwhelming decisions that leave many potential investors stuck before they ever get started. But one Houston-based company is solving that problem by offering a structured, full-support approach to real estate investing that removes the friction from every step of the process.

Automated REI Group, founded by real estate investor and entrepreneur Jordan Turnbow, is changing the way people enter the real estate space—especially when it comes to navigating the Section 8 housing market. With a background in real estate acquisitions, property management, and affordable housing strategy, Turnbow built the company to give both new and seasoned buyers a clear, actionable system that works.

“Most people want to invest in real estate but don’t know where to begin—or they’ve tried before and ended up frustrated,” says Turnbow. “Our goal isn’t to sell a dream. It’s to make the process real, repeatable, and smooth from start to finish.”

Rather than offering courses or DIY coaching, Automated REI Group walks clients through a five-phase, structured model that ensures no detail is missed. The process includes:

  • Market and property research tailored to each investor’s goals
  • Hands-on support with offer structuring, contracts, and due diligence
  • Inspection coordination and negotiation assistance
  • Section 8 landlord application and onboarding guidance
  • Property manager vetting, onboarding, and system setup

This approach has attracted professionals, business owners, and retirees across the country—many of whom are looking for a reliable and efficient way to get involved in real estate without having to navigate the learning curve on their own.

A key focus for the company is investor protection and long-term clarity. Every property sourced through Automated REI Group goes through multiple rounds of review and compliance checks, including Section 8 eligibility screening, rehab estimates, and risk evaluations before it’s presented to a client.

In a market where the headlines often highlight unpredictability, Automated REI Group is leaning into structure, transparency, and delivery. Their process is especially popular among buyers who want real estate in their portfolio but don’t have time to become experts in zoning laws, property codes, or tenant screening.

What makes the model unique is its balance of high-touch service and proven systems—giving clients a white-glove experience while keeping the process predictable, documented, and efficient.

Automated REI Group is currently onboarding a limited number of clients each month and offers free consultations to those looking to learn more about their Section 8 acquisition process.

To learn more about Automated REI Group or to schedule a consultation, visit www.automatedreigroup.com.

Media Contact
Company Name: Automated REI Group
Contact Person: Jordan Turnbow
Email: Send Email
Phone: (346) 510-4607
City: Houston
State: Texas
Country: United States
Website: www.automatedreigroup.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Automated REI Group Launches Systemized Approach to Simplify Section 8 Real Estate Investing

24/7 Digital Lifeline Debuts in NC: Mold Remediation Hotline Tackles Wilmington Flooding & Winston-Salem Humidity Risks

“Certified mold testing company in Wilmington and Winston-Salem North Carolina”
Mold Remediation Hotline unveils 24/7 Emergency Hub to combat mold crises in Wilmington’s flood zones and Winston-Salem’s humid suburbs. Instantly connect with EPA-certified specialists via click-to-call or real-time quotes—day or night. “Mold doesn’t clock out, and neither do we,” declares founder Hugh Butcher. Contractors undergo FBI-level vetting (licenses, insurance, 5-star reviews).

Wilmington, NC | Winston-Salem, NC – Apr 22, 2025 – Mold Remediation Hotline, a leader in environmental safety solutions, has launched a groundbreaking 24/7 Emergency Mold Response Platform for residents and businesses in Wilmington, Winston-Salem, and surrounding regions. The digital tool revolutionizes access to certified mold removal experts, offering immediate relief for households battling hazardous infestations.

24/7 Lifeline for Mold Emergencies

The platform enables users to instantly connect with rigorously vetted professionals via click-to-call or by submitting project details for real-time quotes. Every contractor is screened for state licensing, insurance, verified customer reviews, and proven expertise in handling water damage and mold crises. Homeowners can compare transparent pricing, availability, and service profiles—all at zero cost and with no obligation.

“Mold doesn’t adhere to business hours, and neither do we,” emphasized Hugh Butcher, Founder of Mold Remediation Hotline. “In coastal Wilmington and inland Winston-Salem, humidity and flooding create ticking time bombs for health risks like asthma or structural decay. Our platform erases the guesswork, delivering trusted help within minutes—even at 2 AM.”

Combating North Carolina’s Silent Health Crisis

With EPA studies linking delayed mold remediation to chronic respiratory illnesses, the service addresses a critical need in North Carolina’s moisture-heavy climate. Rapid response is vital: post-storm flooding and persistent humidity in cities like Wilmington fuel mold colonies that threaten 1 in 3 homes annually. Yet, locating reliable contractors remains a hurdle.

“Families shouldn’t gamble with unverified ‘experts’ during a mold emergency,” Butcher added. “We’ve eliminated that risk by handpicking mold removal specialists who meet federal safety standards.”

A Post-Pandemic Surge in Health-Centric Innovation

The launch aligns with soaring demand for 24/7 digital home services, as 72% of homeowners now prioritize health-focused upgrades post-COVID. The platform also empowers local small businesses, boosting visibility for licensed specialists in competitive markets like Winston-Salem’s growing suburbs.

About Mold Remediation Hotline

Founded in 2008, Mold Remediation Hotline partners with certified professionals nationwide to deliver swift, EPA-compliant mold removal. Serving all 50 states, the company combines hyperlocal expertise with cutting-edge technology to safeguard homes and businesses.

Media Contact
Company Name: Mold Remediation Hotline
Contact Person: Hugh Butcher
Email: Send Email
Phone: (888) 919-2434
Address:525 Kemper Lane
City: Salt Lake City
State: Utah
Country: United States
Website: https://www.moldremediationhotline.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: 24/7 Digital Lifeline Debuts in NC: Mold Remediation Hotline Tackles Wilmington Flooding & Winston-Salem Humidity Risks

On Earth Day and Every Day The Gloria Barron Prize for Young Heroes Celebrates Youth who are Protecting the Planet

“”With all that nature gives us — wisdom, inspiration, connection — it’s only right that we give something back,” says T.A. Barron. “Our Barron Prize young heroes remind me that each of us has the power to be a steward of this Earth, whether by planting a tree, reducing waste, or simply sharing our love of nature with others.””
The Gloria Barron Prize for Young Heroes, an award that honors inspiring youth across the U.S. and Canada, celebrates young conservationists on Earth Day and all year long. Established in 2001 by author T. A. Barron, the Barron Prize honors outstanding young leaders ages 8 to 18 who have made a significant positive difference to people or the environment. Barron believes passionately that each of us can and should play a part in protecting the natural world.

The Barron Prize celebrates these recent winners who are deeply committed to protecting the planet:

Artash Nath created MonitorMyOcean.com to investigate how human activities affect underwater ocean noise and marine mammals, particularly whales. His system uses data from hydrophones (underwater microphones) to estimate human-caused ocean noise, which disrupts whales’ communication and navigation. He aims to aid whale conservation, such as the design of policies to reduce collisions between whales and the world’s 80,000 commercial ships.

Arya Gurumukhi invented a novel catalyst to improve upon the Bionic Leaf technology, a solar-powered device that mimics photosynthesis to create a highly efficient, alcohol-based fuel from just water, sunlight, and bacteria. She envisions her clean, sustainable energy source as a way to reduce our dependence on fossil fuels, mitigate climate change, and reduce energy insecurity.

Cash Daniels protects freshwater ecosystems and has removed more than 35,000 pounds of trash from the Tennessee River, the world’s most microplastics-polluted river. He has partnered with Tennessee State Parks to place more than 150 fishing line collection bins across the state, protecting waterways and the animals who easily become entangled in the line. Cash funds his collection bins with money earned by recycling aluminum cans – more than three tons of them to date.

Elizabeth Djajalie works passionately to protect Alaska’s ecosystems and way of life by conducting research to help conserve Pacific salmon. She also leads the student arm of the Alaska Science and Engineering Fair (ASEF), a statewide nonprofit that supports STEM education for Alaska youth.

Esther Bonney founded Nurture Natives to protect native plant species. Her nonprofit educates adults and children about the increasing problems non-natives pose to agriculture, pollinators, and homeowners. Her youth-led group hosts plant giveaways across Maryland and has distributed more than 47,000 native seedlings. The group has also planted 2.2 million seeds and donated $24,000 worth of native plants to underprivileged communities.

Genshu Price created Bottles4College to recycle cans and bottles, using the proceeds to help students in Hawaii attend college. Over the past three years, his nonprofit has recycled more than 1.5 million cans and bottles, diverting 100,000 pounds of trash from landfills. In 2023, Genshu awarded Hawaii high school seniors his first round of scholarships – nearly $22,000, raised five cents at a time.

Nirbhuy Arun & Alexis Nicholson co-founded Kids for Urban Trees and have planted more than 300 trees at schools, parks, and low-income housing complexes in their community. The two friends started their club to address the urban heat effect and to develop young environmental stewards.

Varin Sikka invented AirCat, a Direct Air Capture system that removes carbon dioxide from the air on a large scale and holds the potential to significantly mitigate climate change. Varin’s system makes use of the world’s 300,000 wind turbines that provide renewable energy.

For more info visit www.barronprize.org.

About the Barron Prize

Established in 2001 by author T. A. Barron, the Barron Prize is a national award that annually honors 25 outstanding young leaders ages 8 to 18 who have made a significant positive difference to people and the environment. Fifteen top winners each receive $10,000 to support their service work or higher education. These young people are as diverse as their service projects. They are female and male, urban and rural, and from a wide variety of backgrounds across the U.S. and Canada. All of them demonstrate heroic character qualities like courage, compassion, and perseverance. Through the years, the Barron Prize has earned the support of Girl Scouts of the USA, The Wilderness Society, Youth Service America, and Jane Goodall’s Roots & Shoots, among other organizations. 

To learn more about the Barron Prize, visit www.barronprize.org

Media Contact
Company Name: CATHY CALLEGARI PUBLIC RELATIONS INC
Contact Person: Liz Ammirato
Email: Send Email
Phone: 914-299-3882
Address:159 Madison Avenue, Apt. 5J
City: New York
State: NY
Country: United States
Website: www.callprinc.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: On Earth Day and Every Day The Gloria Barron Prize for Young Heroes Celebrates Youth who are Protecting the Planet

$32 Million Reported for Q1 of 2025 for Global Communications Company with a Multi-Stream On-Track for $1B Target: Raadr, Inc., Doing Business as Telvantis (Stock Symbol: RDAR)

$32 Million Reported for Q1 of 2025 for Global Communications Company with a Multi-Stream On-Track for $1B Target: Raadr, Inc., Doing Business as Telvantis (Stock Symbol: RDAR)
$RDAR $300M Platform Offering Proprietary CPaaS Capabilities for High-Volume, Reliable Messaging, Voice and Digital Communications
  • U.S.-Based Communications Technology Company Delivering Global Enterprise Communication Solutions.
  • $300M+ Platform with a Multi-Stream Revenue Model and a Clear Plan to Scale Toward $1B in Annual Revenues.
  • Proprietary CPaaS Capabilities for High-Volume, Reliable Messaging, Voice and Digital Communications.
  • Expanding Partnerships in High-Growth Sectors Including Fintech, Healthcare, and e-Commerce.
  • Accelerating Growth with $32 Million in Revenue Reported Across February and March of 2025.
  • 2025 Growth Plan Prioritizing Revenue Generation, Strategic Acquisitions and Sustainable Shareholder Value Creation.
  • Legacy Debt Cleaned Up, Removed Shell Risk Designations and Completed Foundational Integrations.
  • Expanding CPaaS Services Across Fintech, e-Commerce and Healthcare Sectors with Customers Already in Active Onboarding.
  • Secured Global Partnerships Built a Global Telecom and Enterprise Customer Base with Over 300 Carrier Relationships and Growing Software Licensing Deals.
  • Acquisition Talks with Select U.S. and International Companies That Align with RDAR Growth and Margin Expansion Objectives.
  • Share Buyback Intentions When Appropriate and Aligned with Shareholder Value.
  • Uplisting Potential with a Commitment to Meeting Standards for a National Exchange Listing.

Raadr, Inc., doing business as Telvantis (OTC: RDAR), is a U.S.-based communications technology company powering global enterprise communication. Leveraging extensive carrier relationships and proprietary CPaaS (Communications Platform as a Service) capabilities, RDAR delivers high-volume, reliable messaging, voice, and digital communication solutions. With a strong foothold and expanding partnerships in high-growth sectors like fintech, healthcare, and e-commerce, RDAR is executing its strategy to become a leader in the communications technology space.

RDAR company objective include:

Drive innovation: continuously pioneer cutting-edge technology to enhance telecommunications services worldwide.

Expand reach: build lasting partnerships with leading telcos and enterprises across global markets.

Elevate service quality: Deliver reliable, high-impact solutions that elevate industry standards and client success.

Foster Growth: Leverage our entrepreneurial roots to adapt and grow within an evolving industry landscape.

$32M+ in Revenue Across February and March; Business Plan Relaunch Gaining Momentum On April 21st RDAR announced approximately $32 million in revenue across February and March 2025, confirming strong execution of its business relaunch and growth strategy. With $12.5 million in February and $19.6 million in March, the company’s revenue trajectory continues to accelerate, validating the RDAR position as an emerging force in the telecom technology space. This milestone comes on the heels of RDAR completing its legacy debt remediation and officially entering the next phase of scalable operations. RDAR Gross Margin totaled approximately $1 million over these two months and generated a slight positive operating profit before financing costs. The complete RDAR financial statements will be included in the Company’s quarterly report, which is due May 15, 2025.

Transition from Restructuring to Execution Launches Phase 2 of Growth Plan

On April 10th RDAR announced the official launch of Phase 2 of its 2025 growth strategy. With the final stage of debt remediation now complete, RDAR is shifting into full execution mode, prioritizing revenue generation, strategic acquisitions and sustainable shareholder value creation.

This milestone marks a turning point in the RDAR story. Phase 1 focused on stabilizing the company by cleaning up legacy debt, removing shell risk designations, and completing foundational integrations. With those goals accomplished, RDAR is now entering a new chapter of aggressive expansion and market execution.

“Phase 2 is all about momentum, discipline, and strategic scaling,” said Daniel Contreras, CEO of RDAR. “Weve done the hard work of repositioning the company. Now, we’re building on that foundation by accelerating real revenue, strengthening our operations, and moving closer to our uplisting objectives.

Phase 2 priorities:

Enterprise Revenue Acceleration: Expanding RDAR CPaaS services across fintech, e-commerce, and healthcare sectors with customers already in active onboarding.

Strategic Acquisitions: Advancing talks with select U.S.-based and international companies that align with RDAR growth and margin expansion objectives.

Audit Completion & Transparency: Finalizing financial audits to support future filings and uplisting efforts.

Operational Execution: Optimizing internal systems, processes, and leadership structures for long-term scalability.

Market Visibility: Delivering more frequent shareholder updates, investor engagement content, and performance milestones.

RDAR Completes Final Stage of Legacy Debt Remediation, Paving the Way for New Growth Phase

On April 1st RDAR announced the completion of its final round of debt remediation and legacy clean-up efforts that began in late 2024. Since taking operational control of RDAR in 2024, the current management team has been focused on rebuilding the company with a clear goal: to transform RDAR into a high-growth technology and communications platform under the Telvantis brand. That transformation required addressing years of legacy debt, broken agreements, toxic funders, and outdated contracts – issues that prevented meaningful forward progress.

What’s Been Done Since Taking Over RDAR

Corporate Rebranding & Vision Shift Transitioned from Raadr to Telvantis, a telecom-technology hybrid company focused on CPaaS (Communications Platform as a Service), global connectivity, and AI-driven communications.

Resolved Outstanding Liabilities Settled or remediated toxic and restrictive legacy debt instruments that weighed on the companys operations and market reputation.

Filed Updated Disclosures Improved transparency and made strategic filings to align with uplisting goals.

Built a $300M+ Revenue Platform As outlined in the Investor Education Series, RDAR has developed a multi-stream revenue model and a clear plan to scale toward $1B in annual revenues.

Announced Buyback Intentions Confirmed intent to pursue RDAR share buybacks when appropriate and aligned with shareholder value.

Secured Global Partnerships Built a global telecom and enterprise customer base with over 300 carrier relationships and growing software licensing deals.

RDAR also has NASDAQ Uplisting potential with a commitment to meeting the standards for a national exchange listing.

For more information on $RDAD visit: www.telvantis.com

Company Name: Raadr, Inc., doing business as Telvantis (OTC: RDAR)

X Account: https://x.com/Telvantis

LinkedIn: https://www.linkedin.com/company/telvantis/posts/?feedView=all&viewAsMember=true

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Raadr, Inc
Contact Person: Daniel Contreras, CEO
Email: Send Email
Phone: +1 (954)456-3191
Address:1680 Michigan Avenue
City: Miami Beach
State: Florida
Country: United States
Website: www.telvantis.com

Inventive AI Launches AI RFP Agent to Revolutionize RFP Teams, Enabling 90% Faster Responses and 50% Higher Win Rates

Inventive AI, a cutting-edge platform transforming how companies respond to Requests for Proposals (RFPs), today announced the official launch of its AI RFP Agent, a next-generation AI agent designed to help sales, proposal and solutions teams craft winning proposals in a fraction of the time. This launch marks a major leap forward in enterprise sales automation, bringing powerful AI capabilities to streamline one of the most time-consuming processes in B2B sales.

Among the early adopters is Insider, a global leader in personalized marketing, cross-channel customer experiences, which has reported a 50% increase in win rate and 90% faster response times since deploying Inventive AI’s RFP Agent.

Inventive AI’s RFP AI solution uses advanced language models, knowledge retrieval, and secure workflows to automatically generate high-quality first drafts in minutes. By centralizing organizational knowledge sources and reducing manual effort, Inventive helps teams focus on crafting compelling, tailored proposals that win. The platform also streamlines knowledge source management, reducing the overhead of maintaining content sources to nearly zero.

“Our mission is to build AI agents that help sales teams win deals,” said Gaurav Nemade, Co-founder of Inventive AI. “With the launch of dedicated AI RFP agents, we’re bringing AI deeper into the sales stack, freeing teams from tedious processes and helping them focus on what matters most: Closing.”

Built by a founding team with experience at Google and Stanford, and backed by Y Combinator and top-tier venture firms, Inventive AI is on a mission to transform B2B sales through intelligent AI automation.

“Overall, my RFP workflow is SO much faster now with Inventive and we are winning more than ever before,” said Anthony Pukal Solutions Consultant at Insider.

Inventive AI is now available for sales, proposal and solutions teams worldwide. For more information, visit www.inventive.ai

Media Contact
Company Name: Inventive AI
Contact Person: Mukund Kumar
Email: Send Email
Country: United States
Website: https://www.inventive.ai/

Spinocerebellar Ataxia Drugs Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

“Spinocerebellar Ataxia Drugs Market”
Spinocerebellar Ataxia Companies are IntraBio, Reprocell, Kissei Pharmaceutica, VICO Therapeutics, Steminent, Biohaven, and others.

(Albany, USA) DelveInsight’s “Spinocerebellar Ataxia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Spinocerebellar Ataxia, historical and forecasted epidemiology as well as the Spinocerebellar Ataxia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Spinocerebellar Ataxia, offering comprehensive insights into the Spinocerebellar Ataxia revenue trends, prevalence, and treatment landscape. The report delves into key Spinocerebellar Ataxia statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Spinocerebellar Ataxia therapies. Additionally, we cover the landscape of Spinocerebellar Ataxia clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Spinocerebellar Ataxia treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Spinocerebellar Ataxia space.

The Spinocerebellar Ataxia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Spinocerebellar Ataxia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Spinocerebellar Ataxia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Spinocerebellar Ataxia market.

 

To Know in detail about the Spinocerebellar Ataxia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spinocerebellar Ataxia Market Forecast

 

Some of the key facts of the Spinocerebellar Ataxia Market Report:

  • The Spinocerebellar Ataxia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In February 2025, Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the US Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for troriluzole for the treatment of adult patients with spinocerebellar ataxia (SCA) and has granted Priority Review. This designation is assigned to applications for drugs that would offer a significant improvement over other available treatments for a given disorder or would provide a treatment option where none exists. In the case of SCA, a rare, genetic, neurodegenerative disease, troriluzole would be the first and only FDA-approved treatment for this life-threatening disorder. The FDA’s decision regarding the NDA is expected within 6 months of filing (during 3Q2025). Based on FDA Priority Review timelines and if ultimately approved, Biohaven is prepared to commercialize troriluzole for SCA in the US in 2025.
  • In September 2024, Steminent Biotherapeutics completed the construction of its cell therapy manufacturing facility for Stemchymal®, its pioneering stem cell-based treatment for spinocerebellar ataxia. The company intends to submit provisional drug license applications in Japan and Taiwan by 2025 to support product launches. Additionally, Steminent is preparing to file a Phase 2b clinical trial application with the FDA by 2025
  • The worldwide prevalence of spinocerebellar ataxia ranges from 1 to 5 cases per 100,000 individuals, while in Europe, it is estimated between 0.9 and 3 per 100,000. SCA3 is the most common subtype, accounting for 25% to 50% of cases, followed by SCA2 (13% to 18%), SCA6 (13% to 15%), and SCA7, in descending order of occurrence.
  • According to Bhandari et al. (2023), the global prevalence of spinocerebellar ataxia ranges from 1 to 5 per 100,000, while the overall prevalence in Europe is between 0.9 and 3 per 100,000, with regional variations such as 2 per 100,000 in Italy. Spinocerebellar Ataxia 3 is the most common type, accounting for 25% to 50% of cases, followed by Spinocerebellar Ataxia 2 (13% to 18%), Spinocerebellar Ataxia 6 (13% to 15%), and Spinocerebellar Ataxia 7.
  • Key Spinocerebellar Ataxia Companies: Biohaven, VICO Therapeutics, IntraBio, Kissei Pharmaceutica, Steminent, Reprocell, and others
  • Key Spinocerebellar Ataxia Therapies: Troriluzole (BHV-4157), VO659, IB1001, ROVATIRELIN, Stemchymal, and others
  • The Spinocerebellar Ataxia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spinocerebellar Ataxia pipeline products will significantly revolutionize the Spinocerebellar Ataxia market dynamics.

 

Spinocerebellar Ataxia Overview

Spinocerebellar Ataxia (SCA) is a group of rare, progressive genetic disorders that affect the cerebellum, spinal cord, and sometimes other parts of the nervous system. Characterized by a gradual loss of coordination and balance, SCA typically manifests in adulthood but can also appear earlier in life depending on the subtype. Patients with Spinocerebellar Ataxia often experience difficulties with walking, hand-eye coordination, speech (dysarthria), and in some cases, vision and cognitive function.

There are more than 40 known subtypes of Spinocerebellar Ataxia, each caused by different genetic mutations. The most common types include SCA1, SCA2, SCA3 (Machado-Joseph Disease), and SCA6. Diagnosis involves neurological exams, family history analysis, and genetic testing to identify the specific mutation.

Currently, there is no cure for Spinocerebellar Ataxia, and treatment is primarily supportive and symptomatic. Physical therapy, occupational therapy, and speech therapy play crucial roles in managing the condition and improving quality of life. Research is ongoing to understand the underlying mechanisms of Spinocerebellar Ataxia and develop targeted therapies, including gene therapy and disease-modifying drugs. With increasing awareness and advancements in genetic research, the future holds promise for better diagnosis, management, and potential treatment options for individuals affected by Spinocerebellar Ataxia.

 

Get a Free sample for the Spinocerebellar Ataxia Market Forecast, Size & Share Analysis Report: Spinocerebellar Ataxia Treatment Market

 

Spinocerebellar Ataxia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Spinocerebellar Ataxia Epidemiology Segmentation:

The Spinocerebellar Ataxia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Spinocerebellar Ataxia
  • Prevalent Cases of Spinocerebellar Ataxia by severity
  • Gender-specific Prevalence of Spinocerebellar Ataxia
  • Diagnosed Cases of Episodic and Chronic Spinocerebellar Ataxia

 

Download the report to understand which factors are driving Spinocerebellar Ataxia epidemiology trends @ Spinocerebellar Ataxia Prevalence

 

Spinocerebellar Ataxia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinocerebellar Ataxia market or expected to get launched during the study period. The analysis covers Spinocerebellar Ataxia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Spinocerebellar Ataxia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Spinocerebellar Ataxia Therapies and Key Companies

  • Troriluzole (BHV-4157): Biohaven
  • VO659: VICO Therapeutics
  • IB1001: IntraBio
  • ROVATIRELIN: Kissei Pharmaceutica
  • Stemchymal: Steminent/Reprocell

 

Discover more about therapies set to grab major Spinocerebellar Ataxia market share @ Spinocerebellar Ataxia Medication and FDA Approvals

 

Spinocerebellar Ataxia Market Strengths

  • Increasing recognition of Spinocerebellar Ataxias and their impact on quality of life is driving research and development.
  • Innovative research methodologies and technologies, such as gene therapy and biomarkers, are enhancing the understanding of Spinocerebellar Ataxias.

 

Spinocerebellar Ataxia Market Drivers

  • New drug candidates in development present opportunities for breakthroughs in treatment.
  • Partnerships between academic institutions, biotech companies, and research organizations can enhance data sharing and innovation.

 

Scope of the Spinocerebellar Ataxia Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Spinocerebellar Ataxia Companies: Biohaven Ltd. (NYSE: BHVN), VICO Therapeutics B.V. (Private), IntraBio Inc. (Private), Kissei Pharmaceutical Co., Ltd. (TSE: 4547), Steminent Biotherapeutics Inc. (Private), Reprocell Inc. (TSE: 4978), among others.
  • Key Spinocerebellar Ataxia Therapies: Troriluzole (BHV-4157), VO659, IB1001, ROVATIRELIN, Stemchymal, and others
  • Spinocerebellar Ataxia Therapeutic Assessment: Spinocerebellar Ataxia current marketed and Spinocerebellar Ataxia emerging therapies
  • Spinocerebellar Ataxia Market Dynamics: Spinocerebellar Ataxia market drivers and Spinocerebellar Ataxia market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Spinocerebellar Ataxia Unmet Needs, KOL’s views, Analyst’s views, Spinocerebellar Ataxia Market Access and Reimbursement

 

To know more about Spinocerebellar Ataxia companies working in the treatment market, visit @ Spinocerebellar Ataxia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Spinocerebellar Ataxia Market Report Introduction

2. Executive Summary for Spinocerebellar Ataxia

3. SWOT analysis of Spinocerebellar Ataxia

4. Spinocerebellar Ataxia Patient Share (%) Overview at a Glance

5. Spinocerebellar Ataxia Market Overview at a Glance

6. Spinocerebellar Ataxia Disease Background and Overview

7. Spinocerebellar Ataxia Epidemiology and Patient Population

8. Country-Specific Patient Population of Spinocerebellar Ataxia

9. Spinocerebellar Ataxia Current Treatment and Medical Practices

10. Spinocerebellar Ataxia Unmet Needs

11. Spinocerebellar Ataxia Emerging Therapies

12. Spinocerebellar Ataxia Market Outlook

13. Country-Wise Spinocerebellar Ataxia Market Analysis (2020–2034)

14. Spinocerebellar Ataxia Market Access and Reimbursement of Therapies

15. Spinocerebellar Ataxia Market Drivers

16. Spinocerebellar Ataxia Market Barriers

17. Spinocerebellar Ataxia Appendix

18. Spinocerebellar Ataxia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinocerebellar Ataxia Drugs Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

“Follicular Lymphoma Treatment Market”
Follicular Lymphoma Companies are Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others.

(Albany, USA) DelveInsight’s “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Follicular Lymphoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Follicular Lymphoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Follicular Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Follicular Lymphoma market.

 

To Know in detail about the Follicular Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Follicular Lymphoma Market Forecast

 

Key highlights of the Follicular Lymphoma Market Report:

  • The Follicular Lymphoma market size was valued ~USD 1,082 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In February 2025, Regeneron Pharmaceuticals announced the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company expects a decision from the FDA in the second half of 2025.
  • In February 2025, Genmab A/S (Nasdaq: GMAB) announced that the Japan Ministry of Health, Labour, and Welfare has approved EPKINLY Registered (epcoritamab) for treating patients with relapsed or refractory follicular lymphoma (FL; Grades 1 to 3A) who have undergone two or more prior treatments. This approval makes EPKINLY the first and only subcutaneously administered T-cell engaging bispecific antibody approved in Japan for both relapsed or refractory FL and large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma, after two or more prior therapies.
  • In January 2025, CRISPR Therapeutics announced plans to collaborate with regulatory authorities to determine the next steps for CTX112 in B-cell malignancies, with an update anticipated by mid-2025.
  • In September 2024, The FDA granted Priority Review status to the Biologics License Application (BLA) for odronextamab, intended for the treatment of adults with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) who have not responded to at least two prior systemic therapies.
  • In 2024, approximately 35,000 cases of follicular lymphoma were diagnosed across the 7MM.
  • In 2024, the United States generated around USD 1,082 million in revenue.
  • In 2024, Germany represented the largest market size among the EU4 and the UK, with an estimated value of around USD 108 million.
  • In 2024, Spain had the smallest market size among the EU4 and the UK, with an estimated value of around USD 61 million.
  • In 2024, the United States had the highest number of Follicular Lymphoma cases among the 7MM, with approximately 17,000 cases. This number is expected to rise by 2034.
  • In 2024, the 60-80 age group had the highest incidence of follicular lymphoma, with around 9,000 cases, followed by the 40-59 age group with approximately 4,000 cases.
  • In 2024, stage IV follicular lymphoma cases accounted for approximately 34% of all cases.
  • In 2024, the incidence of follicular lymphoma in the EU4 and the UK was approximately 14,000, with Germany reporting the highest number of cases.
  • Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others
  • Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
  • The Follicular Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics.

 

Follicular Lymphoma Overview

Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma that arises from B-lymphocytes, a type of white blood cell essential for the immune system. Follicular Lymphoma typically originates in the lymph nodes but can also affect the bone marrow and spleen. This form of lymphoma is characterized by the formation of abnormal follicles within lymph nodes, leading to painless swelling, fatigue, night sweats, and unexplained weight loss.

Follicular Lymphoma most commonly affects adults over the age of 60 and is usually diagnosed through a combination of physical examination, blood tests, imaging studies, and biopsy. Genetic testing may also be used to identify specific mutations, such as the BCL2 gene rearrangement, which is often associated with this disease.

Follicular Lymphoma treatment options vary depending on the stage and symptoms, ranging from active surveillance in early stages to targeted therapies, immunotherapy, chemotherapy, and radiation therapy in more advanced or symptomatic cases. While Follicular Lymphoma is generally considered incurable, it is highly treatable, and many patients live for years with proper disease management.

Follicular Lymphoma research continues to advance, with clinical trials exploring novel therapies aimed at improving outcomes and extending progression-free survival, making the future more hopeful for affected patients.

 

Get a Free sample for the Follicular Lymphoma Market Report: Follicular Lymphoma Treatment Market

 

Follicular Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Follicular Lymphoma Epidemiology Segmentation:

The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

  • Total Prevalence of Follicular Lymphoma
  • Prevalent Cases of Follicular Lymphoma by severity
  • Gender-specific Prevalence of Follicular Lymphoma
  • Diagnosed Cases of Episodic and Chronic Follicular Lymphoma

 

Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ Follicular Lymphoma Epidemiology Forecast

 

Follicular Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Follicular Lymphoma Therapies and Key Companies

  • LUNSUMIO (mosunetuzumab): Roche
  • BRUKINSA (zanubrutinib): BeiGene
  • YESCARTA: Kite Pharma
  • MONJUVI (tafasitamab): Incyte Corporation
  • AZD0486: AstraZeneca
  • Abexinostat: Xynomic Pharmaceuticals
  • ME-401: MEI Pharma
  • Tisagenlecleucel: Novartis
  • Parsaclisib (IBI376): Innovent Biologics
  • Odronextamab: Regeneron
  • Mosunetuzumab: Genetech
  • Abexinostat: Xynomic Pharma
  • Rituximab IV: Roche
  • Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche
  • Enzastaurin: Eli Lilly and Company
  • Loncastuximab tesirine: ADC Therapeutics S.A
  • Zanubrutinib: BeiGene
  • Bendamustine: Cephalon
  • Tazemetostat: Epizyme, Inc.
  • ibrutinib: Pharmacyclics LLC.
  • Obatoclax mesylate: Gemin X
  • Ibrutinib: AbbVie
  • IXAZOMIB: Millennium Pharma

 

To know more about Follicular Lymphoma companies working in the treatment market, visit @ Follicular Lymphoma Medication, Manufacturers and Therapeutic Assessment

 

Follicular Lymphoma Market Strengths

Follicular lymphoma market has a diverse pipeline,with emergence of novel classes such as bi-specificantibodies, cancer vaccine and allogenic CAR-Ts.

 

Follicular Lymphoma Market Opportunities

R-CHOP continues to be the gold standard of caredespite other therapies or combinations that have tried to advance the treatment paradigm

 

Scope of the Follicular Lymphoma Market Report

  • Study Period: 2020-2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Follicular Lymphoma Companies: AbbVie (NYSE: ABBV), Genentech (subsidiary of Roche), Xynomic Pharma (OTC: XYNM), Regeneron (NASDAQ: REGN), Epizyme, Inc. (formerly NASDAQ: EPZM), ADC Therapeutics S.A (NYSE: ADCT), Kite Pharma (subsidiary of Gilead Sciences), Eli Lilly and Company (NYSE: LLY), Cephalon (acquired by Teva), Innovent Biologics (HKEX: 1801), Incyte Corporation (NASDAQ: INCY), Novartis (SWX: NOVN), MEI Pharma (NASDAQ: MEIP), AstraZeneca (LSE: AZN), BeiGene (NASDAQ: BGNE; HKEX: 6160), Millennium Pharma (subsidiary of Takeda), Roche (SWX: ROG), Gemin X (acquired by Cephalon), Pharmacyclics LLC. (formerly NASDAQ: PCYC), Xynomic Pharmaceuticals (OTC: XYNM), and others.
  • Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others
  • Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
  • Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Follicular Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Follicular Lymphoma Market Access and Reimbursement

 

Discover more about therapies set to grab major Follicular Lymphoma drug market share @ Follicular Lymphoma Clinical Trials and FDA Approvals

 

Table of Contents

1. Follicular Lymphoma Market Report Introduction

2. Executive Summary for Follicular Lymphoma

3. SWOT analysis of Follicular Lymphoma

4. Follicular Lymphoma Patient Share (%) Overview at a Glance

5. Follicular Lymphoma Market Overview at a Glance

6. Follicular Lymphoma Disease Background and Overview

7. Follicular Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Follicular Lymphoma

9. Follicular Lymphoma Current Treatment and Medical Practices

10. Follicular Lymphoma Unmet Needs

11. Follicular Lymphoma Emerging Therapies

12. Follicular Lymphoma Market Outlook

13. Country-Wise Follicular Lymphoma Market Analysis (2020-2034)

14. Follicular Lymphoma Market Access and Reimbursement of Therapies

15. Follicular Lymphoma Market Drivers

16. Follicular Lymphoma Market Barriers

17. Follicular Lymphoma Appendix

18. Follicular Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

Prostate Cancer Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight

“Prostate Cancer Clinical Trials”
Prostate cancer companies are Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen, more

(Albany, USA) DelveInsight’s ‘Prostate Cancer Pipeline Insight 2025’ report provides comprehensive global coverage of pipeline prostate cancer in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the prostate cancer pipeline domain.

As per DelveInsight’s assessment, globally, Prostate Cancer pipeline constitutes 150+ key companies continuously working towards developing 160+ Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

Request a sample and discover the recent advances in prostate cancer drugs @ Prostate Cancer Pipeline Report

 

Key Takeaways from the Prostate Cancer Pipeline Report

  • DelveInsight’s prostate cancer pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline prostate cancer drugs.
  • Key prostate cancer companies such as Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, and others are evaluating new prostate cancer drugs to improve the treatment landscape.
  • Promising pipeline prostate cancer such as 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others are under different phases of prostate cancer clinical trials.
  • In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
  • In August 2024, Nuvation Bio announced that the US Food and Drug Administration cleared its investigational new drug application to evaluate NUV-1511, the first clinical candidate from the company’s novel drug-drug conjugate (DDC) platform.
  • In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
  • In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.
  • In June 2024, BioNTech SE and Duality Biologics announced that the US Food and Drug Administration granted Fast Track designation for BNT324/DB-1311 for the treatment of patients with advanced/unresectable, or metastatic castration-resistant prostate cancer (“CRPC”) who have progressed on or after standard systemic regimens.
  • In May 2024, Fusion Pharmaceuticals began the Phase II AlphaBreak trial of FPI-2265 in mCRPC patients.
  • In February 2024, Fusion Pharmaceuticals Inc. announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre. The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture, and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T for the treatment of prostate-specific membrane antigen (PSMA)-expressing cancers. In addition, Fusion and the Licensors have signed an agreement to settle the parties’ dispute related to an inter partes review of a U.S. patent owned by the Licensors which was instituted in August 2023 by the United States Patent and Trademark Board.
  • In February 2024, BioXcel Therapeutics, Inc. announced that the FDA granted Fast Track designation for BXCL701 with a CPI to treat metastatic small cell neuroendocrine prostate cancer (SCNC) in patients progressing on chemotherapy. This designation allows for expedited development and review by the FDA.

 

Find out more about prostate cancer drugs @ Prostate Cancer Pipeline Analysis

 

Prostate Cancer Overview

Prostate Cancer is one of the most common types of cancer affecting men, especially those over the age of 50. Prostate Cancer begins in the prostate gland, a small walnut-shaped gland that produces seminal fluid. Prostate Cancer often develops slowly and may not cause noticeable symptoms in its early stages. However, advanced Prostate Cancer can lead to difficulties in urination, blood in urine and pelvic discomfort.

Prostate Cancer diagnosis typically involves prostate-specific antigen (PSA) blood tests, digital rectal exams (DRE), imaging studies, and biopsies to confirm the presence and stage of the disease. Prostate Cancer risk factors include age, family history, race, and lifestyle choices.

Prostate Cancer treatment options vary depending on the stage and aggressiveness of the disease and may include active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, and immunotherapy. Prostate Cancer patients are also increasingly benefiting from precision medicine and targeted therapies designed to minimize side effects and improve outcomes.

Prostate Cancer awareness and early detection through regular screening play a critical role in improving survival rates. Ongoing research in Prostate Cancer continues to explore advanced diagnostic tools and more effective treatment approaches to enhance patient care.

Currently approved drugs for metastatic prostate cancer include XTANDI by Astellas/Pfizer and ZYTIGA by Janssen, both available for over a decade. Despite the introduction of ZYTIGA generics in the US in 2019 and in the EU since late 2022, causing a significant revenue drop, particularly in the US, ZYTIGA is still being actively studied in combination with emerging therapies, boosting its use with the compound abiraterone acetate.

In 2019, Janssen expanded its portfolio with ERLEADA for mHSPC, following its 2018 approval for nmCRPC. Bayer’s NUBEQA has also rapidly gained momentum, becoming a key competitor. PARP inhibitors have been making strides for patients with HRR gene mutations (BRCA1/2). AstraZeneca’s LYNPARZA was introduced for first-line prostate cancer treatment, while Pharma& Schweiz’s RUBRACA became available for 3L mCRPC patients in 2020. Additionally, in 2023, Pfizer’s TALZENNA, Janssen’s AKEEGA, and AstraZeneca/Merck’s LYNPARZA were approved for first-line use. Myovant Sciences’ ORGOVYX and Sanofi’s JEVTANA have also been approved in the US for treating mCRPC.

In 2022, Novartis’ radioligand therapy, PLUVICTO, was approved for mCRPC treatment, resulting in higher-than-expected revenue in the third-line mCRPC segment. Novartis now plans to expand its presence into earlier-line mCRPC by 2024 and mHSPC by 2025 within the US market.

 

For further information on the prostate cancer pipeline therapeutics, reach out @ Prostate Cancer Therapeutics Market

 

A snapshot of the Pipeline Prostate Cancer Drugs mentioned in the report:

  • 177Lu-PSMA-I&T: Curium
  • Opevesostat (MK-5684; ODM-208): Merck/ Orion
  • Mevrometostat (PF-06821497): Pfizer
  • TRUQAP (capivasertib, AZD5363): AstraZeneca
  • 177Lu-PNT2002: Lantheus
  • 177Lu-DOTA-rosopatamab (TLX591): Telix Pharmaceuticals
  • TAVT-45 (abiraterone acetate): Tavanta Therapeutics
  • Saruparib (AZD5305): AstraZeneca
  • CAN-2409 (aglatimagene besadenovec): Candel Therapeutics
  • Fuzuloparib: Jiangsu Hengrui Pharmaceuticals

 

Learn more about the emerging prostate cancer therapies @ Prostate Cancer Clinical Trials and FDA Approvals

 

Prostate Cancer Therapeutics Assessment

The prostate cancer pipeline report proffers an integral view of the emerging prostate cancer segmented by stage, product type, molecule type, route of administration, and mechanism of action.

 

Scope of the Prostate Cancer Pipeline Report

  • Coverage: Global
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
  • Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: PSMA inhibitors (Prostate-specific Membrane Antigen Inhibitors), CYP11A1 inhibitor, EZH2 inhibitor, Proto-oncogene protein c-akt inhibitor, PSMA-targeted therapy, Ionising radiation emitter, Steroidal inhibitor of CYP17A1, Poly(ADP-ribose) polymerase-1 inhibitor, Thymidine kinase expression stimulants, Poly(ADP-ribose) polymerase 2 inhibitors
  • Key Prostate Cancer Companies: Merck & Co., Inc. (NYSE: MRK), Telix Pharmaceuticals Limited (ASX: TLX), Exelixis, Inc. (NASDAQ: EXEL), AstraZeneca PLC (NASDAQ: AZN), AB Science S.A. (EPA: AB), Lantheus Holdings, Inc. (NASDAQ: LNTH), Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY), MacroGenics, Inc. (NASDAQ: MGNX), Xencor, Inc. (NASDAQ: XNCR), Merus N.V. (NASDAQ: MRUS), Arvinas, Inc. (NASDAQ: ARVN), Candel Therapeutics, Inc. (NASDAQ: CADL), Ipsen S.A. (EPA: IPN), LAVA Therapeutics N.V. (NASDAQ: LVTX), ESSA Pharma Inc. (NASDAQ: EPIX), Poseida Therapeutics, Inc. (NASDAQ: PSTX), Janux Therapeutics, Inc. (NASDAQ: JANX), AbbVie Inc. (NYSE: ABBV), Sorrento Therapeutics, Inc. (OTC: SRNEQ), Avacta Group plc (LSE: AVCT), BeiGene, Ltd. (NASDAQ: BGNE), Duality Biologics (HKEX: 6988), Curium, Modra Pharmaceuticals, Syntrix Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Blue Earth Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, SL VAXiGEN, Nammi Therapeutics, and 858 Therapeutics, and others
  • Key Prostate Cancer Pipeline Therapies: 177Lu-PSMA-I&T, Opevesostat (MK-5684), 177Lu-DOTA-rosopatamab, Cabozantinib, Capivasertib, Masitinib, FPI-2265, 177Lu-PNT2002, Mevrometostat (PF-06821497), Fuzuloparib, ModraDoc006, BMS-986218, Lorigerlimab, SX-682, ZEN-3694, Vudalimab, OPDIVO (nivolumab), Zenocutuzumab, Vobramitamab Duocarmazine, PT-112, LAE201, TAVT-45, pTVG-HP (MVI-816), TAS-115, KPG-121, ARV-766, CAN-2409, Saruparib (AZD5305), 177Lu-rhPSMA-10.1, Tazemetostat (Tazverik), KEYTRUDA, LAVA-1207, Masofaniten (EPI-7386), P PSMA 101, JANX 007, AUR107, MSP008-22, 225Ac-FL-020, NPX267, ABBV-969, SL-T10, Abivertinib, ETX-19477, AVA 6000, QXL138AM, BG-68501, DB-1311, and others

 

Dive deep into rich insights for new prostate cancer treatments, visit @ Prostate Cancer Drugs and Therapies

 

Table of Contents

1. Prostate Cancer Pipeline Report Introduction

2. Prostate Cancer Pipeline Report Executive Summary

3. Prostate Cancer Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Prostate Cancer Clinical Trial Therapeutics

6. Prostate Cancer Pipeline: Late-Stage Products (Pre-registration)

7. Prostate Cancer Pipeline: Late-Stage Products (Phase III)

8. Prostate Cancer Pipeline: Mid-Stage Products (Phase II)

9. Prostate Cancer Pipeline: Early-Stage Products (Phase I)

10. Prostate Cancer Pipeline Therapeutics Assessment

11. Inactive Products in the Prostate Cancer Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Companies

14. Key Products in the Prostate Cancer Pipeline

15. Unmet Needs

16. Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prostate Cancer Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight